GelMEDIX
Latest round
- Seed
Last raised
- Feb 2026
Total raised
- $14M
Investors
- 5
About GelMEDIX
GelMEDIX develops innovative ocular cell therapies aimed at enhancing vision restoration for individuals afflicted by ocular diseases.GelMEDIX Inc. specializes in creating ocular cell therapies to address vision impairment caused by retinal damage. Founded in 2020, the company is headquartered in Cambridge, US. In February 2026, GelMEDIX, Inc., Beacon Angels, Boston Harbor Angels, and TiE Angels.GelMEDIX, Inc. specializes in ocular cell therapy, focusing on engineering innovative formulations designed to enhance cell viability, engraftment, and tissue regeneration, ultimately aiming to restore vision for individuals suffering from various ocular diseases. The company’s core offerings revolve around advanced therapeutic solutions that address critical challenges in ocular health, particularly targeting conditions that compromise vision due to retinal damage or degeneration. GelMEDIX’s products are positioned for clinical applications and are developed to cater to healthcare providers, including hospitals, specialty clinics, and research institutions.The revenue structure of GelMEDIX, Inc. is predicated on direct business-to-business transactions with healthcare providers and research institutions that are interested in cutting-edge ocular therapies. Transactions occur through partnerships and collaborations, with potential licensing agreements that facilitate the distribution and use of their innovative therapeutic products. Specific pricing plans and revenue details are not disclosed, but the company’s revenue streams include one-time fees for therapy applications and ongoing support or subscription-based models for continuous access to their products and research findings. The focus on flagship therapeutic offerings ensures that GelMEDIX can build a sustainable revenue model around the demand for effective ocular cell therapies within the healthcare sector. The company plans to introduce additional products aimed at age-related macular degeneration and other ocular conditions, with a focus on enhancing their therapeutic formulations by 2026. Furthermore, GelMEDIX is strategizing to penetrate new markets in Europe by mid-2026, aligning with their ongoing commitment to address the growing demand for effective ocular treatments.
Who invested in GelMEDIX
5 investors across 2 rounds
See all investors in GelMEDIX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about GelMEDIX
Who invested in GelMEDIX?
GelMEDIX has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GelMEDIX raised?
GelMEDIX has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did GelMEDIX last raise money?
GelMEDIX's most recent round on record is a Seed, in Feb 2026.
What does GelMEDIX do?
GelMEDIX develops innovative ocular cell therapies aimed at enhancing vision restoration for individuals afflicted by ocular diseases.
Where is GelMEDIX headquartered?
GelMEDIX is headquartered in Cambridge, US.
Which VCs invest in companies like GelMEDIX?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at GelMEDIX's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like GelMEDIX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.